Neumora Therapeutics Inc (NMRA) Stock Price, Quote & News

Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associ...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 760 0900

Website: www.neumoratx.com

Address:

260 Arsenal Place, Suite 1, Watertown, United States

Keystone1 Sep. 21 at 1:40 AM

$NMRA up 13% in overnight trading.

0 · Reply

TRLG Sep. 18 at 11:48 PM

$NMRA now it seems unreasonably low.

0 · Reply

XQuise Sep. 18 at 4:52 PM

$NMRA 👀👈🏻

0 · Reply

fantastex Sep. 18 at 2:21 PM

$NMRA 40m cash burn per quarter bankruptcy likely in 2 quarters. Gonna watch for a pump and dump next week....

0 · Reply

fantastex Sep. 18 at 2:21 PM

$NMRA they usually like to hit either 0.67 or 0.66....... will wait for hit

0 · Reply

Ron_Burn Sep. 18 at 12:37 AM

$NMRA watching..

0 · Reply

QulckTrade Sep. 17 at 2:47 PM

$NMRA can we see double bottom and reverse?

0 · Reply

0what Sep. 16 at 2:57 PM

$NMRA 180! why so much manipulation! robbing people of their shares not good

0 · Reply

SizeableVirus Sep. 15 at 9:31 PM

$NMRA Hahahaha, the most brazen robbery of all.

0 · Reply

Jfredwing1 Sep. 15 at 2:15 PM

$NMRA what the heck is going on??

1 · Reply

Neumora CEO transition not a surprise, says H.C. Wainwright

2026-08-16T13:42:58.000Z - 5 weeks ago

Neumora Therapeutics reports Q2 EPS (23c), consensus (24c)

2026-08-16T13:42:40.000Z - 5 weeks ago

Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed

Aug 14, 2026, 9:00 AM EDT - 5 weeks ago

Neumora Therapeutics Slides: Company presentation

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

Neumora Therapeutics Earnings release: Q2 2026

Aug 14, 2026, 7:00 AM EDT - 5 weeks ago

Neumora Therapeutics Quarterly report: Q2 2026

2026-07-27T11:10:51.000Z - 1 month ago

Neumora Therapeutics reports pre-clinical toxicology results from NMRA-215 study

Jul 27, 2026, 7:00 AM EDT - 1 month ago

Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026

2026-07-13T13:25:49.000Z - 2 months ago

Neumora Therapeutics price target lowered to $5 from $7 at RBC Capital

Jul 1, 2026, 8:00 AM EDT - 2 months ago

Neumora Therapeutics Slides: Corporate presentation

2026-06-18T12:11:53.000Z - 3 months ago

Neumora Therapeutics price target lowered to $4 from $6 at Mizuho

Jun 17, 2026, 7:00 AM EDT - 3 months ago

Neumora Therapeutics Slides: Investor presentation

2026-06-16T11:23:08.000Z - 3 months ago

Neumora Therapeutics price target lowered to $5 from $8 at Needham

2026-06-16T10:11:19.000Z - 3 months ago

Neumora Therapeutics price target lowered to $7 from $18 at H.C. Wainwright

2026-06-15T22:35:06.000Z - 3 months ago

Clear Street says Neumora failed trial does not impact LB Pharmaceuticals LB-102

LBRX

2026-06-15T12:55:07.000Z - 3 months ago

Neumora Therapeutics announces KOASTAL studies miss primary endpoint

Jun 15, 2026, 8:13 AM EDT - 3 months ago

Neumora Therapeutics scraps depression drug after two late-stage trial failures

Jun 15, 2026, 8:00 AM EDT - 3 months ago

Neumora Therapeutics Reports Data from Phase 3 KOASTAL Program and Provides Business and Pipeline Update

May 27, 2026, 4:00 PM EDT - 3 months ago

Neumora Therapeutics Transcript: AGM 2026

May 19, 2026, 1:35 PM EDT - 4 months ago

Neumora Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 12, 2026, 4:05 PM EDT - 4 months ago

Neumora Therapeutics to Participate in 2026 RBC Capital Markets Global Healthcare Conference

2026-05-07T15:39:57.000Z - 4 months ago

Neumora Therapeutics reports Q1 EPS (30c), consensus (31c)

May 7, 2026, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 7, 2026, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Slides: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Neumora Therapeutics Quarterly report: Q1 2026

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Neumora Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 months ago

Neumora Therapeutics Proxy statement: Proxy filing

Apr 13, 2026, 10:15 AM EDT - 5 months ago

Neumora Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 6, 2026, 7:00 AM EDT - 5 months ago

Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference

2026-04-02T14:37:16.000Z - 5 months ago

Neumora Therapeutics management to meet with Piper Sandler

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Neumora Therapeutics Earnings Call Transcript: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Neumora Therapeutics Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Neumora Therapeutics Earnings release: Q4 2025

2026-03-30T11:00:07.000Z - 5 months ago

Neumora Therapeutics reports Q4 EPS (35c), consensus (33c)

Mar 30, 2026, 6:53 AM EDT - 5 months ago

Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 30, 2026, 6:30 AM EDT - 5 months ago

Neumora Therapeutics Slides: Corporate presentation

Mar 16, 2026, 7:00 AM EDT - 6 months ago

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

2026-03-02T18:05:39.000Z - 6 months ago

Neumora Therapeutics management to meet virtually with Needham

2026-02-17T11:06:03.000Z - 7 months ago

Neumora upgraded to Outperform from Market Perform at William Blair

Feb 11, 2026, 4:00 PM EST - 7 months ago

Neumora Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 10, 2026, 7:00 AM EST - 7 months ago

Neumora Therapeutics Slides: Corporate presentation

Feb 4, 2026, 7:00 AM EST - 7 months ago

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T10:25:32.000Z - 8 months ago

Neumora Therapeutics initiated with an Outperform at Leerink

2026-01-06T13:05:25.000Z - 8 months ago

Neumora Therapeutics price target raised to $6 from $5 at Mizuho

Jan 5, 2026, 8:00 AM EST - 8 months ago

Neumora Therapeutics Transcript: Study Result

Jan 5, 2026, 8:00 AM EST - 8 months ago

Neumora Therapeutics Press release: Study Result

Jan 5, 2026, 8:00 AM EST - 8 months ago

Neumora Therapeutics Slides: Study Result

2026-01-05T11:42:16.000Z - 8 months ago

Neumora Therapeutics announces results from NMRA-511 Phase 1b study

Jan 5, 2026, 6:35 AM EST - 8 months ago

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Jan 5, 2026, 6:30 AM EST - 8 months ago

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

Nov 12, 2025, 2:00 PM EST - 10 months ago

Neumora Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 2:30 PM EST - 10 months ago

Neumora Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 10 months ago

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 7:00 AM EST - 10 months ago

Neumora Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Neumora Therapeutics Earnings release: Q3 2025

Nov 3, 2025, 7:00 AM EST - 10 months ago

Neumora Therapeutics to Participate in Upcoming Conferences in November

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Transcript: R&D Day 2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Press release: FY 2025

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Neumora Therapeutics Slides: FY 2025

Oct 27, 2025, 7:00 AM EDT - 10 months ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898

Oct 27, 2025, 6:30 AM EDT - 10 months ago

Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Neumora Therapeutics to Host Virtual R&D Day on October 27

Sep 9, 2025, 1:00 PM EDT - 1 year ago

Neumora Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Participate in Upcoming Conferences in September

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:00 PM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Jul 23, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 9, 2025, 4:00 PM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Jul 9, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861

May 16, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings Call Transcript: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Quarterly report: Q1 2025

May 12, 2025, 4:30 PM EDT - 1 year ago

Neumora Therapeutics Earnings release: Q1 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics Slides: Corporate Presentation

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 28, 2025, 7:00 AM EDT - 1 year ago

Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Neumora Therapeutics Proxy statement: Proxy Filing

Apr 4, 2025, 4:05 PM EDT - 1 year ago

NMRA Deadline: NMRA Investors with Losses in Excess of $100K Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 30, 2025, 4:00 PM EDT - 1 year ago

NMRA Deadline: NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 26, 2025, 2:19 AM EDT - 1 year ago

NMRA Investors Have Opportunity to Lead Neumora Therapeutics, Inc. Securities Lawsuit First Filed by The Firm

Mar 4, 2025, 8:30 AM EST - 1 year ago

Neumora Therapeutics to Present at Leerink Global Healthcare Conference

Keystone1 Sep. 21 at 1:40 AM

$NMRA up 13% in overnight trading.

0 · Reply

TRLG Sep. 18 at 11:48 PM

$NMRA now it seems unreasonably low.

0 · Reply

XQuise Sep. 18 at 4:52 PM

$NMRA 👀👈🏻

0 · Reply

fantastex Sep. 18 at 2:21 PM

$NMRA 40m cash burn per quarter bankruptcy likely in 2 quarters. Gonna watch for a pump and dump next week....

0 · Reply

fantastex Sep. 18 at 2:21 PM

$NMRA they usually like to hit either 0.67 or 0.66....... will wait for hit

0 · Reply

Ron_Burn Sep. 18 at 12:37 AM

$NMRA watching..

0 · Reply

QulckTrade Sep. 17 at 2:47 PM

$NMRA can we see double bottom and reverse?

0 · Reply

0what Sep. 16 at 2:57 PM

$NMRA 180! why so much manipulation! robbing people of their shares not good

0 · Reply

SizeableVirus Sep. 15 at 9:31 PM

$NMRA Hahahaha, the most brazen robbery of all.

0 · Reply

Jfredwing1 Sep. 15 at 2:15 PM

$NMRA what the heck is going on??

1 · Reply

Ketomin Sep. 14 at 10:21 PM

$NMRA What was that blip between 4 & 5 pm?

0 · Reply

Kaltycoon Sep. 14 at 7:59 PM

$NMRA entering dead zone, too many set backs

0 · Reply

Jfredwing1 Sep. 14 at 6:15 PM

$NMRA wow, what a fall...

0 · Reply

SizeableVirus Sep. 14 at 5:55 PM

$NMRA FUCKING TRASH....

0 · Reply

Chrissytina Sep. 11 at 6:45 PM

$NMRA This officially now sucks!!! 😡

0 · Reply

cloudforever Sep. 10 at 9:06 PM

$NMRA 2 yrs for nothing 😠 😡 😤

1 · Reply

Only_Bulls Sep. 10 at 6:59 PM

$NMRA I’ve been pretty quiet lately. Obviously this sucks but aside from shorts and lack of interest, any reason why this has dropped so consistently in the last week and a half? Did I miss a bad PR?

2 · Reply

Jfredwing1 Sep. 8 at 7:24 PM

$NMRA ouch

1 · Reply

SizeableVirus Aug. 31 at 1:42 PM

$NMRA hahaha this piece of shit was up 8% in pre-market; the market opens and it's already in the red—hahaha, this garbage is a joke

0 · Reply

Buying_Low_Selling_High Aug. 24 at 1:07 PM

$NMRA To be honest never liked this Bill Aurora guy. Maybe he is getting fired and selling his shares.

0 · Reply

TRLG Aug. 20 at 8:32 PM

$NMRA another one today... clearly they believe in the pipeline still...

1 · Reply

InvestorCG Aug. 19 at 8:35 PM

$NMRA 200000 shares sold by Aurora, the COO, over the past few days. Warm and fuzzy feelings here.

0 · Reply

Market Cap	137.16M
Revenue (ttm)	0.00
Net Income (ttm)	-236.93M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	1.19

Volume	1,674,700
Avg Vol	895,328
Day's Range	N/A - N/A
Shares Out	187.90M
Stochastic %K	3%
Beta	2.71
Analysts	Sell
Price Target	$6.14